Xenetic Biosciences, Inc. SEC filings XBIO
Xenetic Biosciences, Inc. has 484 filings in SEC EDGAR's recent list, going back to Nov 21, 2011. Its latest annual report, Form 10-K, was filed on Mar 12, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 23, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Nov 1, 2024 | — |
| CORRESP | Letter to the SEC | Oct 30, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 25, 2024 | — |
| 25-NSE | Delisting notice | Jul 18, 2024 | — |
| D | Filing | Oct 13, 2022 | — |
| D | Filing | May 4, 2022 | — |
| EFFECT | Filing | Oct 22, 2021 | — |
| CORRESP | Letter to the SEC | Oct 20, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 19, 2021 | — |
| EFFECT | Filing | Aug 23, 2021 | — |
| CORRESP | Letter to the SEC | Aug 19, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 18, 2021 | — |
| D | Filing | Aug 3, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 14, 2020 | — |
| CORRESP | Letter to the SEC | Oct 6, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 5, 2020 | — |
| EFFECT | Filing | Sep 23, 2019 | — |
| CORRESP | Letter to the SEC | Sep 19, 2019 | — |
| UPLOAD | Letter from the SEC | Sep 19, 2019 | — |
| CERT | Filing | Jul 22, 2019 | — |
| 8-A12B | Form 8-a | Jul 22, 2019 | — |
| D | Filing | Jul 18, 2019 | — |
| EFFECT | Filing | Jul 16, 2019 | — |
| CORRESP | Letter to the SEC | Jul 15, 2019 | — |
| CORRESP | Letter to the SEC | Jul 15, 2019 | — |
| CORRESP | Letter to the SEC | Jul 12, 2019 | — |
| CORRESP | Letter to the SEC | Jul 12, 2019 | — |
| CORRESP | Letter to the SEC | Jul 10, 2019 | — |
| CORRESP | Letter to the SEC | Jul 10, 2019 | — |
| CORRESP | Letter to the SEC | Jul 3, 2019 | — |
| CORRESP | Letter to the SEC | Jul 3, 2019 | — |
| 425 | Filing pursuant to rule 425 | Jun 18, 2019 | — |
| 425 | Form 8-k | Jun 13, 2019 | — |
| CORRESP | Letter to the SEC | May 24, 2019 | — |
| EFFECT | Filing | May 22, 2019 | — |
| UPLOAD | Letter from the SEC | May 21, 2019 | — |
| CORRESP | Letter to the SEC | May 21, 2019 | — |
| 425 | Form 8-k amendment | May 20, 2019 | — |
| 425 | Form 8-k amendment | May 13, 2019 | — |
| 425 | Filing | May 13, 2019 | — |
| CORRESP | Letter to the SEC | Apr 24, 2019 | — |
| UPLOAD | Letter from the SEC | Apr 12, 2019 | — |
| 425 | Prospectus supplement | Apr 1, 2019 | — |
| CT ORDER | Filing | Mar 20, 2019 | — |
| 425 | Form 8-k | Mar 7, 2019 | — |
| D | Filing | Mar 7, 2019 | — |
| 425 | Form 8-k | Mar 5, 2019 | — |
| 425 | Form 8-k | Mar 4, 2019 | — |
| EFFECT | Filing | Oct 12, 2018 | — |
| CORRESP | Letter to the SEC | Oct 9, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 5, 2018 | — |
| CT ORDER | Filing | May 3, 2018 | — |
| DEFR14A | Revised definitive proxy statement | Nov 3, 2017 | — |
| EFFECT | Filing | Nov 1, 2016 | — |
| CERTNAS | Auto-generated paper document | Nov 1, 2016 | — |
| 8-A12B/A | Form 8-a12b | Nov 1, 2016 | — |
| 8-A12B | Form 8-a12b | Nov 1, 2016 | — |
| CORRESP | Letter to the SEC | Oct 31, 2016 | — |
| CORRESP | Letter to the SEC | Oct 31, 2016 | — |
| CORRESP | Letter to the SEC | Oct 28, 2016 | — |
| CORRESP | Letter to the SEC | Oct 28, 2016 | — |
| CORRESP | Letter to the SEC | Oct 26, 2016 | — |
| CORRESP | Letter to the SEC | Oct 26, 2016 | — |
| CORRESP | Letter to the SEC | Oct 26, 2016 | — |
| CORRESP | Letter to the SEC | Oct 24, 2016 | — |
| CORRESP | Letter to the SEC | Oct 24, 2016 | — |
| CORRESP | Letter to the SEC | Oct 11, 2016 | — |
| UPLOAD | Letter from the SEC | Oct 5, 2016 | — |
| CORRESP | Letter to the SEC | Jun 23, 2016 | — |
| UPLOAD | Letter from the SEC | May 23, 2016 | — |
| CT ORDER | Filing | Sep 15, 2015 | — |
| NT 10-Q | Extension | Aug 17, 2015 | Jun 30, 2015 |
| NT 10-Q | Extension | May 18, 2015 | Mar 31, 2015 |
| NT 10-K | Notice of late filing | Apr 1, 2015 | Dec 31, 2014 |
| NT 10-Q | Mainbody | May 15, 2014 | Mar 31, 2014 |
| NT 10-K | Mainbody | Mar 31, 2014 | Dec 31, 2013 |
| NT 10-Q | Mainbody | Jul 15, 2013 | May 31, 2013 |
| NT 10-Q | Mainbody | Apr 15, 2013 | Feb 28, 2013 |
| NT 10-Q | Mainbody | Jan 14, 2013 | Nov 30, 2012 |
| NT 10-K | Mainbody | Nov 29, 2012 | Aug 31, 2012 |
| EFFECT | Filing | Mar 22, 2012 | — |
| CORRESP | Letter to the SEC | Mar 19, 2012 | — |
| UPLOAD | Letter from the SEC | Feb 15, 2012 | — |
| UPLOAD | Letter from the SEC | Jan 20, 2012 | — |
| UPLOAD | Letter from the SEC | Dec 15, 2011 | — |
Showing 85 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Framingham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1534525
- Former names
- General Sales & Leasing, Inc. (until Jan 10, 2014); GENERAL AIRCRAFT INC. (until Feb 12, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.